<ARTICLE> 5 <LEGEND> This schedule contains summary financial information extracted from ICN Pharmaceuticals, Inc.'s March 31, 2000 Consolidated Condensed Financial Statements and is qualified in its entirety by reference to such financial statements. </LEGEND> <MULTIPLIER> 1,000 <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> JAN-01-2000 <PERIOD-END> MAR-31-2000 <CASH> 215,238 <SECURITIES> 0 <RECEIVABLES> 246,130 <ALLOWANCES> (24,950) <INVENTORY> 139,358 <CURRENT-ASSETS> 598,140 <PP&E> 409,172 <DEPRECIATION> (82,490) <TOTAL-ASSETS> 1,496,855 <CURRENT-LIABILITIES> 147,748 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 789 <OTHER-SE> 699,143 <TOTAL-LIABILITY-AND-EQUITY> 1,496,855 <SALES> 159,340 <TOTAL-REVENUES> 192,340 <CGS> 60,766 <TOTAL-COSTS> 60,766 <OTHER-EXPENSES> 4,001 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 15,221 <INCOME-PRETAX> 38,448 <INCOME-TAX> 11,111 <INCOME-CONTINUING> 27,399 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 27,399 <EPS-BASIC> .35 <EPS-DILUTED> .34